Sedation practices in pediatric patients with acute lymphoblastic leukemia

被引:9
|
作者
Nugent, Bethany D. [1 ]
Davis, Peter J. [1 ,2 ]
Noll, Robert B. [1 ]
Tersak, Jean M. [1 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] UPMC, Dept Anesthesiol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA
[3] UPMC, Div Pediat Hematol Oncol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA
关键词
acute lymphoblastic leukemia; anesthesia; late effects of cancer treatment; lumbar puncture; neurotoxicity of therapy; NEUROCOGNITIVE OUTCOMES; GENERAL-ANESTHESIA; PROPOFOL; EXPOSURE; SURVIVORS; NEURONS; CHEMOTHERAPY; OLIGODENDROCYTES; NEUROTOXICITY; VASODILATION;
D O I
10.1002/pbc.28037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The 5-year survival for pediatric acute lymphoblastic leukemia (ALL) is greater than 90%. One late effect of pediatric ALL associated with numerous long-term difficulties is neurocognitive deficits. The experience at our institution, as well as conversations with oncologists at other institutions, suggests an increase in the use of sedation during lumbar punctures (LPs) for treatment of pediatric ALL. Among the most common Children's Oncology Group (COG) ALL protocols, approximately 30 LPs are performed over 2-3 years. Studies in animals reveal that sedation drugs may harm the developing brain. Gaps in knowledge exist regarding their use in children, particularly repeated exposures. The purpose of this study is to summarize sedation practices for LPs related to the treatment of ALL at COG institutions. Methods Responsible Individuals (RIs) of the Cancer Control Committee of COG were invited to complete an internet-based survey about sedation practices at their institutions. Results Surveys were sent to 103 RIs with a 62% response rate (N = 64). A combined 2018 new patients with ALL were seen each year (mean = 31.5, range = 3-110) at the participating institutions. The majority (96%) of children with ALL received sedation for LPs. While there was considerable variability across institutions in the type of sedation given, the most common was propofol alone (n = 36, 56%). Conclusions A substantial number of children with ALL receive sedation for LPs; however, there is variation in the medication used. Better understanding of sedation practices in children with ALL may inform future research to investigate which methods are the safest, with an emphasis on long-term neurocognitive late effects.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Treatment of pediatric acute lymphoblastic leukemia
    Tucci, Fabio
    Arico, Maurizio
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (08): : 1124 - 1128
  • [32] Pharmacogenomics of pediatric acute lymphoblastic leukemia
    Meeker, Nathan D.
    Yang, Jun J.
    Schiffman, Joshua D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1621 - 1632
  • [33] ACUTE KIDNEY INJURY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
    Guo, Nina
    Assanasen, Chatchawin
    Ranch, Daniel
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S81 - S82
  • [34] THE OUTCOME OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS WHO PRESENTED WITH HYPERLEUKOCYTOSIS
    Unal, S.
    Ozsurekci, Y.
    Aytac, S.
    Kuskonmaz, B.
    Tavil, B.
    Tuncer, M.
    Yetgin, S.
    Gurgey, A.
    Gumruk, F.
    Cetin, M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S268 - S268
  • [35] Adrenal Suppression in Pediatric Patients during Treatment for Acute Lymphoblastic Leukemia
    Schlosser, Mary-Pat
    Burd, Daniel
    Ahmet, Alexandra
    Lawrence, Sarah
    Bassal, Mylene
    BLOOD, 2015, 126 (23)
  • [36] Dietary intakes in pediatric patients with acute lymphoblastic leukemia during chemotherapy
    Chatvuttinun, Suthida
    Phoonlapdacha, Phanphen
    Suthutvoravut, Umaporn
    Chongviriyaphan, Nalinee
    FASEB JOURNAL, 2010, 24
  • [37] M-ficolin in pediatric patients at diagnosis of acute lymphoblastic leukemia
    Lechot-Huser, A. S.
    Kurrer, Schmitt A.
    Muthurajah, S.
    Seppele, M.
    Rutsche, J.
    Suter, F. M.
    Schlapbach, L. J.
    Ammann, R. A.
    SWISS MEDICAL WEEKLY, 2017, 147 : 41S - 41S
  • [38] Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia
    Keito Hoshitsuki
    Yinmei Zhou
    April M. Miller
    John K. Choi
    Hope D. Swanson
    Nickhill H. Bhakta
    Sima Jeha
    Seth E. Karol
    Raul C. Ribeiro
    Jeffrey E. Rubnitz
    Charles G. Mullighan
    Cheng Cheng
    Jun J. Yang
    Mary V. Relling
    Ching-Hon Pui
    Hiroto Inaba
    Leukemia, 2023, 37 : 1782 - 1791
  • [39] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [40] COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma
    Hashmi, Saman K.
    Bodea, Jessica
    Patni, Tushar
    Angel, Savannah
    Bhakta, Nickhill H.
    Jeha, Sima
    Karol, Seth E.
    Ribeiro, Raul C.
    Rubnitz, Jeffrey E.
    Wolf, Joshua
    Li, Yimei
    Pui, Ching-Hon
    Hijano, Diego R.
    Inaba, Hiroto
    JAMA NETWORK OPEN, 2024, 7 (02) : E2355727